Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Plaque Psoriasis Clinical Trial

Official title:

Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06005532
• Other study ID #: MABPS-3/2020
• Status: Recruiting
• Phase: Phase 3
• Start date: October 2, 2023
• Est. completion date: December 2025

Study information

• Verified date: November 2023
• Source: Mabscale, LLC
• Contact: Yulia BASKAEVA
• Phone: +74997149289
• Email: baskaeva.y[@]benerix.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.

The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.

Description:

Adalimumab is a recombinant humanized monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to Humira®, which is approved as treatment in patients with chronic plaque psoriasis.

This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 494
• Est. completion date: December 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Written informed consent.

2. Male and female patients aged 18-65 years, body weight = 50 kg and = 120 kg.

3. Established clinical diagnosis plaque psoriasis, lasting at least 6 months before the screening.

4. Plaque psoriasis of moderate or severe severity of stable course with:

• PASI = 12 points;

• BSA = 10 %;

• sPGA = 3 points.

5. Patients who have been shown to undergo systemic therapy and/or patients who have had insufficient therapeutic efficacy of at least 1 previous standard systemic therapy for psoriasis, including phototherapy, therapy with cytostatic and immunosuppressive drugs, or who have had intolerance to standard systemic therapy.

Exclusion Criteria:

1. Data on intolerance or hypersensitivity to any components of the drugs, or to any other human proteins, immunoglobulin preparations.

2. A history of severe hypersensitivity reactions of any etiology.

3. Other (other than plaque) forms of psoriasis.

4. Drug-induced psoriasis.

5. Data on the use of the Adalimumab or any preparations of monoclonal antibodies inhibiting TNF-a at any time during life.

6. The presence of Adalimumab antibodies.

7. Extensive surgical intervention performed less than 30 days before the screening period, or planned extensive surgical intervention during the study period.

8. Active or latent tuberculosis

9. Lymphoproliferative diseases, lymphoma, leukemia, myeloproliferative diseases or a history of multiple myeloma.

10. Any other malignant neoplasms currently or in anamnesis within the last 5 years, with the exception of completely removed and/or cured.

11. Confirmed coronavirus infection caused by COVID-19 within 8 weeks prior to the screening period.

12. Anamnestic data on the presence of syphilis, viral hepatitis B, viral hepatitis C, HIV.

13. Vaccination with live or attenuated vaccines within 8 weeks before the screening period.

14. Hepatic and/or renal insufficiency.

15. Pregnancy or lactation.

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• Adalimumab
Adalimumab injection 40 mg / 0.8 ml
• Humira
Adalimumab injection 40 mg / 0.4 ml

Locations

Country	Name	City	State
Russian Federation	Regional dermatovenerologic dispensary	Barnaul
Russian Federation	Chelyabinsk Regional Clinical Dermatovenerologic Dispensary	Chelyabinsk
Russian Federation	Interregional Clinical Diagnostic Center	Kazan'
Russian Federation	City clinical hospital n.a.Botkin	Moscow
Russian Federation	Rheumatology research Instititue n.a.Nasonova	Moscow
Russian Federation	State Scientific Center of Dermatovenerology and Cosmetology	Nizhny Novgorod
Russian Federation	Reafan	Novosibirsk
Russian Federation	New Clinic	Pyatigorsk
Russian Federation	Dermatovenerologic dispensary N10	Saint Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Mabscale, LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of patients who achieved a response according to the PASI criterion of 75 (a decrease in the severity and prevalence of psoriasis by =75% from the baseline level assessed by the PASI index)		after 16 weeks of therapy (assessment at Visit 10)
Primary	Proportion of patients with positive antibody titer to Adalimumab		51 weeks of therapy
Primary	Percentage of patients who have neutralizing antibodies to Adalimumab		51 weeks of therapy